Published May 23, 2019 | Version v1
Patent Open

BTK MUTATION AND IBRUTINIB RESISTANCE

  • 1. University of Chicago

Contributors

Patent applicant:

Description

Provided herein are mutations in Bruton's Tyrosine Kinase (BTK) that confer resistance to treatment with a BTK inhibitors, such as Ibrutinib, and compositions and methods for the treatment, diagnosis, and characterization of BTK-inhibitor-resistant cancers.

Files

US20190153543.pdf

Files (1.9 MB)

Name Size Download all
md5:ebf62523223ce440b56ea9bc898d7eab
1.9 MB Preview Download

Additional details

Identifiers

Patent application number
US 201716302015 A
Patent number
US 2019/0153543 A1
Other
oai:uchicago.tind.io:8164

Dates

Patent filed
2017-05-18

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Medicine